|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we analyzed 1) the expression/secretion profile of EN2 in five independent samples cohorts from PCa patients and controls (prostate tissues and/or urine) to determine its utility as a PCa biomarker; and 2) the functional role of EN2 in normal (RWPE1) and tumor (LNCaP/22Rv1/PC3) prostate cells to explore its potential value as therapeutic target.
|
31500112 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among other factors, comparing patients with limited tumor load with negative cases, PVI [odds ratio, OR = 0.521, 95% confidence interval (CI) 0.330-0.824; p < 0.005] and PCI (OR = 0.289, 95% CI 0.180-0.466; p < 0.0001) were inversely associated with the PCA risk.
|
31154465 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
|
31138829 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Via PCA analysis, it was found that miRNA 106b~25 expression in plasma and tumor, T, N and TNM stage were correlated with each other.
|
31384175 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression and pathway enrichment of representative iron intake genes (TFRC and DMT1), utilization genes (FTH1, FTL, HIF1A, HMOX1, SLC25A37, and SLC25A38), and efflux genes (FLVCR1 and SLC40A1) was investigated in tumor and adjacent tissues.
|
30076742 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Hierarchical clustering and PCA analysis of KSHV transcripts revealed three clusters of tumors with different latent and lytic gene expression profiles.
|
30557332 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Various PCa‑targeting strategies in adenovirus‑mediated therapy have been developed to improve tumor‑targeting effects and human safety.
|
28901490 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A new generation of prostate cancer (PCa) biomarkers has emerged, including diagnostic serum and urine markers aimed at refining the identification high-grade tumors and tissue-based gene expression assays offering prognostic and predictive clinical information.
|
27023445 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There has been unprecedented progress in the development of new PCa biomarkers through advancements in proteomics, tissue DNA and protein/RNA microarray, identification of microRNA, isolation of circulating tumor cells, and tumor immunohistochemistry.
|
23806492 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that a typical PCa gene is a prostate-specific transcription factor, kinase, or phosphatase with high interindividual variance of the expression level in adjacent normal prostate tissue and differential expression between normal prostate tissue and primary tumor.
|
23166609 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present method was evaluated by classifying three series of tumors and its robustness, in terms of tumor clustering and prediction, was further compared with that of three classification methods (Gene expression bar code, Top-scoring pair(s) and a PCA-based method).
|
21853153 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Three different analyses were performed: (1) A PCA-based linear discriminant analysis identified a 54 gene profile characteristic of all tumors, (2) Application of MANOVA (Pcorr < .05) to tumor data revealed a larger set of 149 differentially expressed genes.
|
15836779 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas 3/7 PIN specimens associated with nonrecurrent PCA demonstrated euploidy, all 4/7 PIN associated with recurrent disease demonstrated the same aneuploidy for chr9 as the primary tumor.
|
11025389 |
2000 |